Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHRM840 > Dyslipidemia Medication Formulary > Flashcards

Dyslipidemia Medication Formulary Flashcards

1
Q

atorvastatin brand names

A

Atorvaliq
Lipitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

atorvastatin dosing

A

-10-20 mg/day (moderate intensity)
-40-80 mg/day (high intensity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

atorvastatin adverse effects

A

-diarrhea
-arthralgia
-nasopharyngitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

atorvastatin monitoring parameters

A

-lipid panel
-hepatic transaminase levels
-signs/symptoms of myopathy/rhabdomyolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

rosuvastatin brand names

A

Crestor
Ezallor Sprinkle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

rosuvastatin dosing

A

-5-10 mg/day (moderate intensity)
-20-40 mg/day (high intensity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

rosuvastatin adverse effect

A

myalgia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

rosuvastatin monitoring parameters

A

-lipid panel
-hepatic transaminase levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

simvastatin brand names

A

FloLipid
Zocor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

simvastatin dosing

A

20-40 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

simvastatin adverse effects

A

-atrial fibrillation
-edema
-eczema
-abdominal pain
-constipation
-gastritis
-nausea
-cystitis
-increased serum transaminases
-headache
-vertigo
-increased creatine phosphokinase in blood specimen
-myalgia
-bronchitis
-upper respiratory infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

simvastatin monitoring parameters

A

-lipid panel
-hepatic transaminase levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

pravastatin brand name

A

Pravachol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

pravastatin dosing

A

40-80 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

pravastatin adverse effects

A

-musculoskeletal pain
-upper respiratory tract infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

pravastatin monitoring parameters

A

-lipid panel
-hepatic transaminase levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

lovastatin brand name

A

Altoprev

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

lovastatin dosing

A

-20 mg/day (low intensity)
-40-80 mg/day (moderate intensity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

lovastatin adverse effects

A

-infection
-increased creatine phosphokinase in blood specimen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

lovastatin monitoring parameters

A

-lipid panel
-hepatic transaminase levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

pitavastatin brand names

A

Livalo
Zypitamag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

pitavastatin dosing

A

1-4 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

pitavastatin adverse effects

A

-constipation
-diarrhea
-back pain
-myalgia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

pitavastatin monitoring parameters

A

-lipid panel
-hepatic transaminase levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
fluvastatin brand name
Lescol XL
26
fluvastatin dosing
-20-40 mg/day (low intensity) -80 mg/day (moderate intensity)
26
fluvastatin monitoring parameters
-lipid panel -hepatic transaminase levels
26
fluvastatin adverse effects
-headache -fatigue -insomnia -dyspepsia -abdominal pain -diarrhea -nausea -urinary tract infection -myalgia -sinusitis -bronchitis
27
ezetimibe brand name
Zetia
28
ezetimibe dosing
10 mg PO QD
29
ezetimibe adverse effects
-increased serum transaminases -arthralgia -sinusitis -upper respiratory tract infection
30
ezetimibe monitoring parameters
-lipid panel -hepatic transaminase levels
31
evolocumab brand names
Repatha Repatha Pushtronex System Repatha SureClick
32
evolocumab dosing
-140 mg SQ Q2W -420 mg SQ once monthly
33
evolocumab adverse effects
-headache -nasopharyngitis
34
evolocumab monitoring parameters
-lipid profile before initiating treatment -fasting lipid profile 4-12 weeks after starting therapy; every 3-12 months thereafter -signs/symptoms of hypersensitivity reactions
35
alirocumab brand name
Praluent
36
alirocumab dosing
-start at 75 mg SQ Q2W or 300 mg SQ Q4W -can increase up to 150 mg SQ Q2W
37
alirocumab adverse effect
injection site reaction
38
alirocumab monitoring parameters
-lipid profile before initiating treatment -fasting lipid profile 4-12 weeks after starting therapy; every 3-12 months thereafter -for patients taking 300 mg Q4W, measure LDL-C before next scheduled dose -signs/symptoms of hypersensitivity reactions
39
cholestyramine brand names
Prevalite Questran Questran Light
40
cholestyramine dosing
-start at 4 g PO QD/BID; increase gradually over the course of at least 1 month -4-8 g/day PO BID -max dose: 24 g/day
41
cholestyramine adverse effect
constipation
42
cholestyramine monitoring parameters
-lipid profile before initiating treatment -fasting lipid profile 4-12 weeks after starting therapy; every 3-12 months thereafter
43
colesevelam brand name
Welchol
44
colesevelam dosing
-3.75 g PO QD -1.875 g PO BID
45
colesevelam adverse effect
constipation
46
colesevelam monitoring parameters
lipid profile 4-12 weeks after starting therapy; every 3-12 months thereafter
47
colestipol brand names
Colestid Colestid Flavored
48
colestipol dosing
-granules: start at 5 g PO QD/BID; increase by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day PO QD or in divided doses -tablets: start at 2 g PO QD/BID; increase by 2 g PO QD/BID at 1-2 month intervals; maintenance: 2-16 g/day PO QD or in divided doses
49
colestipol adverse effects
-constipation -diarrhea -abdominal pain -nausea -vomiting -heartburn -stomach cramps -flatulence -muscle or joint pain -headache
50
colestipol monitoring parameters
-lipid profile before initiating treatment -fasting lipid profile 4-12 weeks after starting therapy; every 3-12 months thereafter
51
fenofibrate brand names
Antara Fenoglide Lipofen Lofibra TriCor Triglide
52
fenofibrate dosing
-Antara: 130 mg PO QD -Lipofen: 150 mg PO QD -Lofibra: 200 mg PO QD (high cholesterol) or 67 mg PO QD (severe hypertriglyceridemia) -Fenoglide: 120 mg PO QD -Tricor: 160 mg PO QD -Triglide: 160 mg PO QD
53
fenofibrate adverse effects
-increased serum alanine aminotransferase -increased serum aspartate aminotransferase
54
fenofibrate monitoring parameters
-periodic blood counts during first year of therapy -lipid profile within few months of initiation of therapy -LFTs at baseline and periodically during therapy -kidney function for patients with kidney impairment -signs/symptoms of myopathy, myositis, or rhabdomyolysis
55
gemfibrozil brand name
Lopid
56
gemfibrozil dosing
600 mg PO BID 30 minutes before breakfast and dinner
57
gemfibrozil adverse effect
dyspepsia
58
gemfibrozil monitoring parameters
-serum cholesterol -LFTs periodically -CBC periodically during first year of therapy
59
omega-3 fatty acid brand name
Lovaza
60
omega-3 fatty acid dosing
-4 g PO QD -2 g PO BID
61
omega-3 fatty acid adverse effects
-dysgeusia -dyspepsia -eructation
62
omega-3 fatty acid monitoring parameters
-triglycerides and other lipids at baseline and periodically -hepatic transaminase levels periodically for patients with hepatic impairment -signs/symptoms of bleeding
63
icosapent ethyl brand name
Vascepa
64
icosapent ethyl dosing
2 g PO BID with meals
65
icosapent ethyl adverse effect
hemorrhage
66
icosapent ethyl monitoring parameters
-triglycerides and other lipids at baseline and periodically -ALT and AST periodically for patients with hepatic impairment -signs/symptoms of bleeding
67
niacin brand names
Niacin-50 Niacor Niaspan Slo-Niacin
68
niacin dosing
500-2000 mg PO QD-TID
69
niacin adverse effects
-flushing -itching -diarrhea -nausea -vomiting -cough -dry skin -headache
70
niacin monitoring parameters
-blood glucose for diabetic patients -CPK and serum potassium periodically if on concurrent HMG-CoA reductase inhibitor -liver function tests pretreatment, every 6-12 weeks for first year of therapy, periodically thereafter -lipid profile -platelets and PT if on anticoagulants -uric acid if predisposed to gout -phosphorus if predisposed to hypophosphatemia

PHRM840 (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions